Overview: Phospholipase A2 Receptor Antibody TestIntroduction: The Phospholipase A2 Receptor Antibody Test detects PLA2R antibodies to diagnose membranous nephropathy, causing kidney swelling. Following 2023 NKF guidelines, it uses immunoassays for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected membranous nephropathy.
Other Names: PLA2R Antibody Assay, Membranous Nephropathy Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: PLA2R antibody testing began in the 2000s with membranous nephropathy research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects PLA2R antibodies to diagnose membranous nephropathy, guides treatment, and evaluates patients with kidney swelling.
Test Parameters: 1. PLA2R Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of kidney swelling, proteinuria, or renal symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document kidney swelling, proteinuria, or history of kidney disease. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, membranous nephropathy implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect PLA2R antibodies. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for membranous nephropathy diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive PLA2R antibodies confirm membranous nephropathy, guiding immunosuppressive therapy. Negative results may require kidney biopsy.
Specialist Consultation: Consult a nephrologist for result interpretation and treatment planning.
Additional Supporting Tests: Kidney biopsy, urine protein electrophoresis, or anti-PLA2R quantitative testing to confirm membranous nephropathy diagnosis.
Test Limitations: Non-specific for certain kidney diseases; clinical correlation is needed. Sample quality affects sensitivity.
References: NKF Kidney Guidelines, 2023; Kidney International, Beck LH, 2022.
